Pacific Biosciences of California, Inc.
Price Action
Technical Summary
WEAKENINGPacific Biosciences of California, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 23), showing significant lag compared to the market leaders. Earnings growth of 98% provides fundamental context to the price action. Investors should exercise caution due to high volatility (88% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.40 | -5.92% | BELOW |
| 50 SMA | $1.45 | -8.78% | BELOW |
| 100 SMA | $1.52 | -12.96% | BELOW |
| 150 SMA | $1.72 | -23.17% | BELOW |
| 200 SMA | $1.68 | -21.56% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PACB in an uptrend right now?
PACB has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is PACB overbought or oversold?
PACB's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is PACB outperforming the market?
PACB has a Relative Strength (RS) Rating of 23 out of 99. PACB is currently lagging the broader market.
Where is PACB in its 52-week range?
PACB is trading at $1.32, which is 48% of its 52-week high ($2.73) and 14% above its 52-week low ($1.09).
How volatile is PACB?
PACB has a Beta of 2.60 and 52-week volatility of 88%. It's more volatile than the S&P 500 - expect bigger swings.